Development of a BRET2 screening assay using β-arrestin 2 mutants

Journal of Biomolecular Screening

Volumn 9, Issue 4, 2004, Pages 322-333

  Vrecl, Milka ^a   Jorgensen, Rasmus ^b   Pogačnik, Azra ^a   Heding, Anders ^b  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b 7TM Pharma ^*  (Denmark)

Author keywords

Arrestin 2; BRET2; GPCRs; Screening

Indexed keywords

2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ARRESTIN; CLATHRIN; G PROTEIN COUPLED RECEPTOR; ISOPRENALINE; MUTANT PROTEIN; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR AGONIST; NEUROPEPTIDE Y2 RECEPTOR; PINDOLOL; SUBSTANCE P; TACHYKININ RECEPTOR AGONIST; TACHYKININ RECEPTOR ANTAGONIST; HYBRID PROTEIN; RETINA S ANTIGEN;

ANIMAL CELL; ARTICLE; BINDING SITE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; COATED VESICLE; COMPARATIVE STUDY; DISSOCIATION; DOSE RESPONSE; DRUG SCREENING; HUMAN; HUMAN CELL; INTERNALIZATION; MOLECULAR STABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; BIOLOGICAL MODEL; CELL STRAIN COS1; CLASSIFICATION; GENETICS; IN VITRO STUDY; LUMINESCENCE; METABOLISM; METHODOLOGY; MUTATION;

ANIMALS; ARRESTINS; COS CELLS; DRUG EVALUATION, PRECLINICAL; HUMANS; LUMINESCENT MEASUREMENTS; MODELS, BIOLOGICAL; MUTATION; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROKININ-1; RECOMBINANT FUSION PROTEINS;

EID: 2542437470     PISSN: 10870571     EISSN: None     Source Type: Journal    
DOI: 10.1177/1087057104263212     Document Type: Article

References (44)

1. Wise A, Gearing K, Rees S: Target validation of G-protein coupled receptors. Drug Discov Today 2002;7:235-246.
2. Walters WP, Namchuk M: Designing screens: how to make your hits a hit. Nat Rev Drug Discov 2003;2:259-266.
3. Claing A, Laporte SA, Caron MG, Lefkowitz RJ, Perry SJ: Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and β-arrestin proteins. Prog Neurobiol 2002;66:61-79.
4. Perry SJ, Lefkowitz RJ: Arresting developments in heptahelical receptor signaling and regulation. Trends Cell Biol 2002;12:130-138.
5. Oakley RH, Laporte SA, Holt JA, Caron MG, Barak LS: Differential affinities of visual arrestin, β arrestin1, and β arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 2000;275:17201-17210.
6. Oakley RH, Laporte SA, Holt JA, Barak LS, Caron MG, Zhang J, et al: Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor-β-arrestin complexes after receptor endocytosis. J Biol Chem 2001;276:19452-19460.
7. Krupnick JG, Goodman OB Jr, Keen JH, Benovic JL: Arrestin/clathrin interaction: localization of the clathrin binding domain of nonvisual arrestins to the carboxy terminus. J Biol Chem 1997;272:15011-15016.
8. Goodman OB Jr, Krupnick JG, Gurevich VV, Benovic JL, Keen JH: Arrestin/ clathrin interaction: localization of the arrestin binding locus to the clathrin terminal domain. J Biol Chem 1997;272:15017-15022.
9. 2-adrenergic receptor/βarrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci USA 1999;96:3712-3717.
10. 2-adrenergic receptor into clathrin-coated pits. J Biol Chem 2000;275:23120-23126.
11. 2-adaptin. J Biol Chem 2002;277:9247-9254.
12. Zacharias DA, Baird GS, Tsien RY: Recent advances in technology for measuring and manipulating cell signals. Curr Opin Neurobiol 2000;10:416-421.
13. Xu Y, Piston DW, Johnson CH: A bioluminescence resonance energy transfer (BRET) system: application to interacting circadian clock proteins. Proc Natl Acad Sci USA 1999;96:151-156.
14. 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc Natl Acad Sci USA 2000;97:3684-3689.
15. Boute N, Pernet K, Issad T: Monitoring the activation state of the insulin receptor using bioluminescence resonance energy transfer. Mol Pharmacol 2001;60:640-645.
16. Angers S, Salahpour A, Bouvier M: Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annu Rev Pharmacol Toxicol 2002;42:409-435.
17. 2/arrestin assay in stable recombinant cells: a platform to screen for compounds that interact with G protein-coupled receptors (GPCRs). J Recept Signal Transduct Res 2002;22:533-541.
18. Eidne KA, Kroeger KM. Hanyaloglu AC: Applications of novel resonance energy transfer techniques to study dynamic hormone receptor interactions in living cells. Trends Endocrinol Metab 2002;13:415-421.
19. Boute N, Jockers R, Issad T: The use of resonance energy transfer in high-throughput screening: BRET versus FRET. Trends Pharmacol Sci 2002;23:351-354.
20. Xu Y, Kanauchi A, von Arnim AG, Piston DW, Johnson CH: Bioluminescence resonance energy transfer: monitoring protein-protein interactions in living cells. Methods Enzymol 2003;360:289-301.
21. Ramsay D, Kellett E, McVey M, Rees S, Milligan G: Homo- and heterooligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences. Biochem J 2002;365:429-440.
22. 2+ signaling exemplified by the NK1 receptor. J Recept Signal Transduct Res 2002;22:241-252.
23. Vrecl M, Anderson L, Hanyaloglu A, McGregor AM, Groarke AD, Milligan G. et al: Agonist-induced endocytosis and recycling of the gonadotropin-releasing hormone receptor: effect of β-arrestin on internalization kinetics. Mol Endocrinol 1998;12:1818-1829.
24. 2-adrenergic receptors. J Recept Signal Transduct Res 1995;15:677-690.
25. Holst B, Zoffmann S, Elling CE, Hjorth SA, Schwartz TW: Steric hindrance mutagenesis versus alanine scan in mapping of ligand binding sites in the tachykinin NK1 receptor. Mol Pharmacol 1998;53:166-175.
26. 2- adrenergic receptor-green fluorescent protein conjugate. Mol Pharmacol 1997;51:177-184.
27. Oakley RH, Hudson CC, Cruickshank RD, Meyers DM, Payne RE, Rhem SM, et al: The cellular distribution of fluorescently labeled arrestins provides a robust, sensitive, and universal assay for screening G protein-coupled receptors. Assay Drug Dev Techn 2002;1:21-30.
28. Celver J, Vishnivetskiy SA, Chavkin C, Gurevich VV: Conservation of the phosphate-sensitive elements in the arrestin family of proteins. J Biol Chem 2002;277:9043-9048.
29. Kim YM, Benovic JL: Differential roles of arrestin-2 interaction with clathrin and adaptor protein 2 in G protein-coupled receptor trafficking. J Biol Chem 2002;277:30760-30768.
30. Milano SK, Pace HC, Kim YM, Brenner C, Benovic JL: Scaffolding functions of arrestin-2 revealed by crystal structure and mutagenesis. Biochemistry 2002;41:3321-3328.
31. Han M, Gurevich VV, Vishnivetskiy SA, Sigler PB, Schubert C: Crystal structure of β-arrestin at 1.9 Å: possible mechanism of receptor binding and membrane translocation. Structure 2001;9:869-880.
32. Sanders MA, LeVine H III: Desensitization of the neurokinin 1 receptor is mediated by the receptor carboxy-terminal region, but is not caused by receptor internalization. J Neurochem 1996;67:2362-2372.
33. Schmidlin F, Dery O, Bunnett NW, Grady EF: Heterologous regulation of trafficking and signaling of G protein-coupled receptors: β-arrestin- dependent interactions between neurokinin receptors. Proc Natl Acad Sci USA 2002; 99:3324-3329.
34. Hosoi T, Koguchi Y, Sugikawa E, Chikada A, Ogawa K, Tsuda N. et al: Identification of a novel human eicosanoid receptor coupled to G(i/o). J Biol Chem 2002;277:31459-31465.
35. 2-adrenergic receptor sequestration: intracellular complement of β-adrenergic receptor kinase and β-arrestin determine kinetics of internalization. Mol Pharmacol 1997;51:800-808.
36. Hemmila IA, Hurskainen P: Novel detection strategies for drug discovery. Drug Discov Today 2002;7:5150-5156.
37. Oakley RH, Laporte SA, Holt JA, Barak LS, Caron MG: Association of β-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. J Biol Chem 1999;274:32248-32257.
38. Kovoor A, Celver J, Abdryashitov RI, Chavkin C, Gurevich VV: Targeted construction of phosphorylation-independent β-arrestin mutants with constitutive activity in cells. J Biol Chem 1999;274:6831-6834.
39. Gurevich VV, Benovic JL: Mechanism of phosphorylation-recognition by visual arrestin and the transition of arrestin into a high affinity binding state. Mol Pharmacol 1997;51:161-169.
40. αq/11. G-protein receptor kinase-2/3. and β-arrestin-1/2. Mol Biol Cell 1998;9:2305-2324.
41. McConalogue K, Dery O, Lovett M, Wong H, Walsh JH, Grady EF, et al: Substance P-induced trafficking of β-arrestins: the role of β-arrestins in endocytosis of the neurokinin-1 receptor. J Biol Chem 1999;274:16257-16268.
42. Pan L, Gurevich EV, Gurevich VV: The nature of the arrestin-receptor complex determines the ultimate fate of the internalized receptor. J Biol Chem 2003;278:11623-11632.
43. Ferguson SS, Downey WE III, Colapietro AM, Barak LS, Menard L, Caron MG: Role of β-arrestin in mediating agonist-promoted G protein-coupled receptor intemalization. Science 1996;271:363-366.
44. Kroeger KM, Hanyaloglu AC, Seeber RM, Miles LE, Eidne KA: Constitutive and agonist-dependent homo-oligomerization of the thyrotropin-releasing hormone receptor: detection in living cells using bioluminescence resonance energy transfer. J Biol Chem 2001;276:12736-12743.